Edition:
United Kingdom

Glenmark Pharmaceuticals Ltd (GLEN.NS)

GLEN.NS on National Stock Exchange of India

575.45INR
21 May 2019
Change (% chg)

Rs-1.25 (-0.22%)
Prev Close
Rs576.70
Open
Rs580.00
Day's High
Rs585.40
Day's Low
Rs566.20
Volume
516,221
Avg. Vol
608,033
52-wk High
Rs711.90
52-wk Low
Rs493.50

Latest Key Developments (Source: Significant Developments)

Glenmark Pharmaceuticals Ltd Gets ANDA Approval For Solifenacin Succinate Tablets
Tuesday, 21 May 2019 

May 21 (Reuters) - Glenmark Pharmaceuticals Ltd ::RECEIVES ANDA APPROVAL FOR SOLIFENACIN SUCCINATE TABLETS, 5 MG AND 10 MG.  Full Article

India's Glenmark Pharmaceuticals Gets ANDA Approval For Esomeprazole Magnesium Delayed-Release Capsules
Tuesday, 14 May 2019 

May 14 (Reuters) - Glenmark Pharmaceuticals Ltd ::GETS ANDA APPROVAL FOR ESOMEPRAZOLE MAGNESIUM DELAYED-RELEASE CAPSULES USP, 20 MG AND 40 MG.  Full Article

Glenmark Pharmaceuticals Ltd Says Its Experimental Rhinitis Treatment Met Main Goal In Phase 3 Study
Wednesday, 8 May 2019 

May 8 (Reuters) - Glenmark Pharmaceuticals Ltd ::GLENMARK PHARMACEUTICALS LTD - K PHARMACEUTICALS ANNOUNCES RESULTS FROM A PHASE 3 STUDY OF RYALTRIS™, AN INVESTIGATIONAL PRODUCT FOR TREATMENT OF SEASONAL ALLERGIC RHINITIS, IN PATIENTS AGED 6 TO UNDER 12 YEARS.GLENMARK PHARMACEUTICALS - STUDY OF RYALTRIS IN PEDIATRIC PATIENTS AGED 6 TO UNDER 12 YEARS OF AGE MET ITS PRIMARY ENDPOINT.GLENMARK PHARMACEUTICALS- RESULTS FROM PHASE 3 STUDY OF RYALTRIS CONSISTENT WITH EXTENSIVE CLINICAL TRIAL EXPERIENCE WITH RYALTRIS IN PATIENTS 12 YRS OF AGE, OLDER.GLENMARK PHARMACEUTICALS LTD - IF APPROVED BY FDA, RYALTRIS WILL BE COMMERCIALIZED BY GLENMARK THERAPEUTICS INC USA.  Full Article

Glenmark Pharmaceuticals Launches Anti‐Diabetes Drug Remogliflozin In India
Tuesday, 30 Apr 2019 

April 30 (Reuters) - Glenmark Pharmaceuticals Ltd ::SAYS LAUNCHES ANTI‐DIABETES DRUG REMOGLIFLOZIN IN INDIA.  Full Article

Glenmark Pharmaceuticals Gets ANDA Approval For Clindamycin And Benzoyl Peroxide Gel
Friday, 15 Mar 2019 

March 15 (Reuters) - Glenmark Pharmaceuticals Ltd ::GETS ANDA APPROVAL FOR CLINDAMYCIN AND BENZOYL PEROXIDE GEL.  Full Article

Glenmark Pharmaceuticals Gets ANDA Approval For Telmisartan And Hydrochlorothiazide Tablets
Tuesday, 5 Mar 2019 

March 5 (Reuters) - Glenmark Pharmaceuticals Ltd ::GOT ANDA APPROVAL FOR TELMISARTAN AND HYDROCHLOROTHIAZIDE TABLETS USP, 40 MG/12.5 MG, 80 MG/12.5 MG, AND 80 MG/25 MG.  Full Article

Glenmark Pharmaceuticals Gets ANDA Approval For Sevelamer Hydrochloride Tablets
Monday, 11 Feb 2019 

Feb 11 (Reuters) - Glenmark Pharmaceuticals Ltd ::SAYS RECEIVES ANDA APPROVAL FOR SEVELAMER HYDROCHLORIDE TABLETS, 400 MG AND 800 MG.  Full Article

Glenmark Pharmaceuticals Gets Tentative ANDA Approval For Abiraterone Acetate Tablets USP
Wednesday, 23 Jan 2019 

Jan 23 (Reuters) - Glenmark Pharmaceuticals Ltd ::SAYS GETS TENTATIVE ANDA APPROVAL FOR ABIRATERONE ACETATE TABLETS USP.  Full Article

India's Glenmark Pharmaceuticals Enters Into Dermatology Segment In U.S
Wednesday, 19 Dec 2018 

Dec 19 (Reuters) - Glenmark Pharmaceuticals Ltd ::SAYS ENTRY INTO BRANDED DERMATOLOGY SEGMENT IN UNITED STATES VIA UNIT.SAYS UNIT GLENMARK THERAPEUTICS INTENDS TO LAUNCH OTHER BRANDED DERMATOLOGY PRODUCTS OVER NEXT 12 MONTHS.BRANDED PORTFOLIO FOR THE U.S MARKET WILL BE DEVELOPED AND COMMERCIALIZED BY GLENMARK HOLDING 'S GLENMARK THERAPEUTICS.  Full Article

India's Glenmark Pharmaceuticals Receives ANDA Approval For Teriflunomide Tablets
Friday, 16 Nov 2018 

Nov 16 (Reuters) - Glenmark Pharmaceuticals Ltd ::RECEIVES ANDA APPROVAL FOR TERIFLUNOMIDE TABLETS, 7 MG AND 14 MG.  Full Article

Photo

Novartis's new treatment for hives outperforms Xolair in trials

ZURICH Novartis said on Tuesday it was taking its experimental medicine ligelizumab to late-stage trials after the drug showed signs of outperforming existing product Xolair in treating severe urticaria, also known as hives.